Review and Approval

Why It Matters

The streamlined process lowers development expenses and accelerates competition, which can translate into lower biologic drug prices for patients and payers.

Key Takeaways

• FDA uses abbreviated pathway to approve biosimilars, reducing trial costs
• Biosimilars must show analytical, animal, and clinical similarity to reference product
• Interchangeable biosimilars need extra switching studies for pharmacy substitution
• Approval may cover indications without direct studies if scientifically justified
• Biosimilar market aims to lower biologic costs and broaden access

Pulse Analysis

Biologic medicines have become the fastest‑growing therapeutic class in the United States, accounting for a sizable share of healthcare spending. Recognizing the need for affordable alternatives, the Biologics Price Competition and Innovation Act of 2009 gave the FDA authority to create an abbreviated approval pathway for biosimilars. This regulatory route focuses on demonstrating that a candidate product is highly similar to an already approved reference biologic in terms of structure, function, and clinical performance, allowing manufacturers to bypass many of the costly, large‑scale trials required for new biologics.

The FDA’s evaluation framework requires a tiered data package. Core analytical studies establish molecular and functional likeness, while animal studies may address toxicology concerns. Clinical components—pharmacokinetic, pharmacodynamic, and immunogenicity assessments—are tailored to the residual uncertainty after analytical work. Importantly, the agency can grant indication extrapolation when the totality of evidence supports safety and efficacy across all approved uses of the reference product, even without direct studies in each indication. For interchangeable biosimilars, an additional switching study is mandated to prove that patients can safely alternate between the biosimilar and the reference product without loss of efficacy.

The practical impact of this pathway is twofold. First, reduced development timelines and lower trial costs encourage more entrants, fostering price competition that can shave tens of percent off biologic therapy costs. Second, the interchangeable designation streamlines pharmacy substitution, expanding patient access while preserving prescriber intent. As more biosimilars gain market share, payers and providers can expect a gradual easing of the financial burden associated with high‑cost biologics, while maintaining rigorous safety standards.